Sandoz has an unwavering commitment to increasing patient access to high-quality, life-enhancing biosimilars. Sandoz is the global market leader and currently markets three biosimilars outside the US, each of which occupies the #1 biosimilar position in its respective category. Sandoz has a leading pipeline with several biosimilars across the various stages of development, including five programs in Phase III clinical trials/filing preparation.


Court ruling paves the way for launch of Sandoz’s Zarxio as first US biosimilar

July 22, 2015

The US Court of Appeals for the Federal Circuit issued a ruling on July 21 that paves the way for Sandoz to launch Zarxio (filgrastim) after September 2, as the first US biosimilar.


Biosimilars: The Sandoz Way
Joerg Windisch talks about biosimilars development and manufacturing at Sandoz.

Watch the video

Biosimilar medicines offer physicians more choices at affordable prices thereby increasing patient access without increasing overall spending.

Read more

Bending the curve of rising healthcare costs without compromising access to quality medical care for its citizens remains one of the most daunting challenges that governments are faced with.

Read more